Neuronetics, Inc. has filed a preliminary prospectus supplement to offer shares of its common stock, a strategic move aimed at raising capital for the company. This development is significant as it highlights Neuronetics' commitment to enhancing its market position within the surgical and medical instruments sector.
The filing, submitted on November 10, 2026, indicates that Neuronetics plans to offer an unspecified number of shares of common stock. The company has previously stated that it is a "smaller reporting company" under federal securities laws, which allows it to comply with certain reduced public company reporting requirements.
Background
Neuronetics, Inc. operates in the surgical and medical instruments and apparatus industry, classified under SIC code 3841. The company is publicly traded on the Nasdaq under the ticker symbol "STIM." Its headquarters are located in Malvern, Pennsylvania. Neuronetics is known for its innovative NeuroStar Advanced Therapy System, a non-invasive treatment for mental health conditions.
What the Filing Says
The filing states, "We are offering shares of our common stock," but does not specify the number of shares or the pricing details. It also notes that the last reported sale price of the company's stock on November 9, 2026, was $2.18 per share. The document emphasizes the risks associated with investing in the company's stock, urging potential investors to read the risk factors outlined in the prospectus.
Impact
This offering may affect a range of stakeholders, including existing shareholders, potential investors, and the broader medical technology industry. By raising capital, Neuronetics aims to strengthen its financial position and invest in further product development and market expansion. The move also positions the company to compete more effectively against established players like Medtronic and Boston Scientific.
What's Next
The filing does not specify what happens next regarding the offering, including the timeline for the sale of shares or any subsequent filings. However, it indicates that the underwriters have been granted an option to purchase additional shares, which could suggest plans for a larger capital raise.
This prospectus supplement reflects Neuronetics’ ongoing efforts to secure funding for its operations and growth in a competitive industry. As the company navigates this process, it will be crucial for investors to stay informed about developments and potential impacts on their investments.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










